Recurrent Mantle Cell Lymphoma Clinical Trials in Columbus

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
Y
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
N
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Suspended
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +25 more
  • Birmingham, Alabama
  • +23 more
2022-03-05
Mar 5, 2022
J
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
2022-02-24
Feb 24, 2022
N
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Active, not recruiting
  • Recurrent Mantle Cell Lymphoma
  • Saint Louis, Missouri
  • +3 more
2022-02-12
Feb 12, 2022
K
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
2021-09-29
Sep 29, 2021
N
Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) - 2021
Terminated
  • Recurrent Anaplastic Large Cell Lymphoma
  • +7 more
  • Los Angeles, California
  • +18 more
2021-07-20
Jul 20, 2021
D
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
2021-05-13
May 13, 2021
K
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
2021-02-20
Feb 20, 2021
K
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma - 2019
Completed
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma
  • +18 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2019-07-29
Jul 29, 2019
N
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma - 2014
Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Anaheim, California
  • +81 more
2018-10-02
Oct 2, 2018
O
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - 2017
Terminated
Has Results
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +10 more
  • Atlanta, Georgia
  • +1 more
2018-05-03
May 3, 2018
A
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma - 2017
Completed
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +66 more
  • Pharmacodynamic Studies
  • +3 more
  • Columbus, Ohio
    The Ohio State University James Cancer Hospital
2018-05-31
May 31, 2018
N
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers - 2012
Completed
  • Adult Acute Myeloid Leukemia in Remission
  • +41 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2017-09-22
Sep 22, 2017
N
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma - 2015
Terminated
Has Results
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +27 more
  • Columbus, Ohio
    Ohio State University Medical Center
2016-06-27
Jun 27, 2016
N
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Completed
  • Anaplastic Large Cell Lymphoma
  • +58 more
  • Columbus, Ohio
    Ohio State University Medical Center
2013-09-27
Sep 27, 2013
N
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Completed
  • B-cell Adult Acute Lymphoblastic Leukemia
  • +52 more
  • rituximab
  • +3 more
  • Columbus, Ohio
    Ohio State University Medical Center
2013-06-05
Jun 5, 2013
N
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Withdrawn
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +6 more
  • bendamustine hydrochloride
  • +2 more
  • Columbus, Ohio
    Arthur G. James Cancer Hospital and Solove Research Institute at
2013-06-05
Jun 5, 2013
N
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Completed
  • Recurrent Adult Burkitt Lymphoma
  • +2 more
  • Columbus, Ohio
    Ohio State University Medical Center
2013-06-03
Jun 3, 2013
N
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Terminated
  • Adult Acute Basophilic Leukemia
  • +34 more
  • Columbus, Ohio
    Ohio State University Medical Center
2013-06-03
Jun 3, 2013
N
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Completed
  • B-cell Chronic Lymphocytic Leukemia
  • +42 more
  • Columbus, Ohio
    Ohio State University Medical Center
2013-06-03
Jun 3, 2013